BTRX-335140
BTRX-335140, or BTRX-140, is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder.[1][2][3] As of February 2020, it is in phase 2 clinical trials for this indication.[2]
| Clinical data | |
|---|---|
| Other names | BTRX-140; CYM-53093 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H32FN5O2 |
| Molar mass | 453.562 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
- κ-Opioid receptor § Antagonists
- List of investigational antidepressants
References
- "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Retrieved 2020-01-25.
- "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
- Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.